Back to search

Article

Affinity Maturation and Characterization of the Novel Monoclonal Antibody (mAb) PB-223 Targeting Cancer- Specific Core 2 O-Glycans

2026-06-03

Abstract excerpt

<h4>Background: </h4> Enhancing the binding affinity of monoclonal antibodies (mAbs) has the potential to improve their therapeutic efficacy. In this study, we generated a novel mAb, PB-223, through affinity maturation of the parental antibody NEO-102. NEO-102 (Ensituximab) is a chimeric human IgG1 mAb that targets a cancer-specific glycosylated variant of MUC5AC expressed on colorectal and pancreatic cancers, whi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d3736d3b-37d2-572d-9fb7-857acb1d4627
DOI
10.20944/preprints202606.0312.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Affinity Maturation and Characterization of the Novel Monoclonal Antibody (mAb) PB-223 Targeting Cancer- Specific Core 2 O-GlycansDOI 10.20944/preprints202606.0312.v1
Select a neighboring publication to make it the new centre.